Hemophilia Clinical Trials 2024

Hemophilia Clinical Trials 2024

Hemophilia research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in hemophilia clinical trials today.

Hemophilia Clinical Trials

Here are the 6 most popular medical studies for Hemophilia

Popular filter options for Hemophilia trials

Hemophilia A Clinical Trials

View 37 Hemophilia A medical studies.

Hemophilia B Clinical Trials

View 14 Hemophilia B medical studies.

Phase 3 Hemophilia Clinical Trials

View 51 phase 3 hemophilia medical studies.

Hemophilia Clinical Trials With No Placebo

View 51 hemophilia medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to Hemophilia

What are the top hospitals conducting Hemophilia research?

When it comes to advancing the treatment and care for individuals with Hemophilia, several hospitals are leading the way in clinical trials. In Chicago, Rush University Medical Center is at the forefront of research with five ongoing trials focused on this rare bleeding disorder. With a history dating back to 2006 when they conducted their first Hemophilia trial, Rush University has since accumulated a total of 14 studies dedicated to improving the lives of those affected by this condition. Meanwhile, McMaster University Medical Centre in Hamilton, Canada has made significant strides as well. Despite being relatively new to conducting Hemophilia trials since 2017, they have already launched five active investigations.

In Toronto's St. Michael's Hospital, researchers are also putting forth considerable effort with five ongoing Hemophilia trials and eight completed studies since delving into this field in 2008. Furthermore, Arkansas Children’s Hospital holds its place among the top institutions contributing to Hemophilia research where they currently have five active clinical trials and nine completed ones that commenced back in 2011.

On the West Coast of the United States lies another key player making a difference: The Orthopaedic Institute for Children located in Los Angeles. Although smaller in scale compared to others on this list, they have four ongoing Hemophilia trials and participated in an additional five previously conducted studies after initiating their first trial related to hemophiliac patients' welfare back around six years ago since2015.

These hospitals represent beacons of hope for individuals living with Hemophilia worldwide who face daily challenges due to uncontrolled bleeding tendencies triggered by even minor injuries or spontaneous occurrences within their bodies. By actively engaging in these clinical trials — investigating new therapies or improving existing treatments — medical professionals are working towards finding innovative approaches that could potentially transform lives positively while ensuring better management options for future generations impacted by this hereditary blood disorder

Which are the best cities for Hemophilia clinical trials?

In the realm of Hemophilia clinical trials, several cities are at the forefront of research and development. Los Angeles, California leads with 25 active trials focusing on promising treatments like efanesoctocog alfa (BIVV001), Damoctocog alfa-pegol (Jivi, BAY94-9027), and BAX 888. Hamilton, Ontario follows closely behind with 22 ongoing studies investigating therapies such as PF-06741086 and PF-06838435 (formerly SPK-9001). Additionally, Sacramento, California boasts 17 active trials exploring treatments like SB-525 (PF-07055480) and valoctocogene roxaparvovec. These cities offer individuals living with Hemophilia access to cutting-edge clinical trials that pave the way for advancements in care and improved quality of life.

Which are the top treatments for Hemophilia being explored in clinical trials?

Exciting advancements are being made in Hemophilia research, with several potential treatments showing promise in ongoing clinical trials. Leading the way is emicizumab, currently being explored in four active trials and 18 all-time Hemophilia studies since its introduction in 2015. Another contender worth mentioning is PF-06741086, which has garnered attention with two active and five all-time Hemophilia trials since its listing in 2017. Additionally, valoctocogene roxaparvovec and fitusiran have both demonstrated potential as they undergo testing in two active trials each. These innovative therapies bring hope for improved management of this genetic bleeding disorder that affects many individuals worldwide.

What are the most recent clinical trials for Hemophilia?

Exciting advancements are being made in the field of hemophilia, with recent clinical trials offering promising insights into potential treatment options. One notable study is investigating aPCC-emicizumab, a novel therapeutic approach for individuals with hemophilia. Alongside this, the efficacy of coagulation Factor VIIa (Recombinant) is also being evaluated as a potential treatment option. Additionally, marstacimab (PF-06741086), an innovative drug candidate, is undergoing Phase 3 trials to assess its effectiveness in managing hemophilia symptoms. These studies bring hope and anticipation for improved therapies that can enhance the quality of life for those living with this condition.

What Hemophilia clinical trials were recently completed?

Recently, several important clinical trials in the field of hemophilia have reached completion, offering potential advancements in treatment. In February 2021, a trial sponsored by Bioverativ, a Sanofi company, concluded its investigation into efanesoctocog alfa (BIVV001). This was followed by another trial for the same therapy completed in November 2019. Furthermore, Genzyme, a Sanofi Company, successfully finished their Fitusiran trial in July 2018. Earlier studies included an Emicizumab trial sponsored by Hoffmann-La Roche that ended in January 2017 and another Emicizumab trial completed in September 2016. These significant milestones highlight ongoing efforts to improve outcomes for individuals living with hemophilia and bring hope to patients worldwide.